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Abstract

The ability of a bis-amino mitoxantrone anticancer drug (named WEHI-150) to form covalent adducts with
DNA, after activation by formaldehyde, has been studied by electrospray ionisation mass spectrometry and
HPLC. Mass spectrometry results showed that WEHI-150 could form covalent adducts with
d(ACGCGCGT)2 that contained one, two or three covalent links to the octanucleotide, whereas the control
drugs (daunorubicin and the anthracenediones mitoxantrone and pixantrone) only formed adducts with one
covalent link to the octanucleotide. HPLC was used to examine the extent of covalent bond formation of
WEHI-150 with d(CGCGCG)2 and d(CG5MeCGCG)2. Incubation of WEHI-150 with d(CG5MeCGCG)2
in the presence of formaldehyde resulted in the formation of significantly greater amounts of covalent adducts
than was observed with d(CGCGCG)2. In order to understand the observed increase of covalent adducts
with d(CG5MeCGCG)2, an NMR study of the reversible interaction of WEHI-150 at both CpG and
5MeCpG sites was undertaken. Intermolecular NOEs were observed in the NOESY spectra of
d(ACGGCCGT)2 with added WEHI-150 that indicated that the drug selectively intercalated at the CpG sites
and from the major groove. In particular, NOEs were observed from the WEHI-150 H2,3 protons to the H1′
protons of G3 and G7 and from the H6,7 protons to the H5 protons of C2 and C6. By contrast,
intermolecular NOEs were observed between the WEHI-150 H2,3 protons to the H2′′ proton of the 5MeC3
in d(CG5MeCGCG)2, and between the drug aliphatic protons and the H1′ proton of G4. This demonstrated
that WEHI-150 preferentially intercalates at 5MeCpG sites, compared to CpG sequences, and predominantly
via the minor groove at the 5MeCpG site. The results of this study demonstrate that WEHI-150 is likely to
form interstrand DNA cross-links, upon activation by formaldehyde, and consequently exhibit greater
cytotoxicity than other current anthracenedione drugs.
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Graphical Abstract

WEHI-150

WEHI-150 reversibly bound with DNA

The ability of the anthracenedione anticancer drug WEHI-150 to form covalent adducts with
DNA, after activation by formaldehyde, has been studied by mass spectrometry, HPLC and
NMR spectroscopy.
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Abstract
The ability of a bis-amino mitoxantrone anticancer drug (named WEHI-150) to form covalent
adducts with DNA, after activation by formaldehyde, has been studied by electrospray
ionisation mass spectrometry and HPLC. Mass spectrometry results showed that WEHI-150
could form covalent adducts with d(ACGCGCGT)2 that contained one, two or three covalent
links to the octanucleotide, whereas the control drugs (daunorubicin and the anthracenediones
mitoxantrone and pixantrone) only formed adducts with one covalent link to the
octanucleotide. HPLC was used to examine the extent of covalent bond formation of WEHI150 with d(CGCGCG)2 and d(CG5MeCGCG)2. Incubation of WEHI-150 with
d(CG5MeCGCG)2 in the presence of formaldehyde resulted in the formation of significantly
greater amounts of covalent adducts than was observed with d(CGCGCG)2. In order to
understand the observed increase of covalent adducts with d(CG5MeCGCG)2, an NMR study
of the reversible interaction of WEHI-150 at both CpG and 5MeCpG sites was undertaken.
Intermolecular NOEs were observed in the NOESY spectra of d(ACGGCCGT)2 with added
WEHI-150 that indicated that the drug selectively intercalated at the CpG sites and from the
major groove. In particular, NOEs were observed from the WEHI-150 H2,3 protons to the
H1' protons of G3 and G7 and from the H6,7 protons to the H5 protons of C2 and C6. By
contrast, intermolecular NOEs were observed between the WEHI-150 H2,3 protons to the
H2" proton of the 5MeC3 in d(CG5MeCGCG)2, and between the drug aliphatic protons and the
H1' proton of G4. This demonstrated that WEHI-150 preferentially intercalates at 5MeCpG
sites, compared to CpG sequences, and predominantly via the minor groove at the 5MeCpG
site. The results of this study demonstrate that WEHI-150 is likely to form interstrand DNA
cross-links, upon activation by formaldehyde, and consequently exhibit greater cytotoxicity
than other current anthracenedione drugs.
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Introduction
Anthracyclines (e.g. daunorubicin, see Figure 1) are an important class of anticancer agents
that continue to play a significant role in the treatment of cancer.1-3 However, their clinical
use is limited by their cardiotoxicity.4 This dose-limiting toxicity has promoted the search for
new anthracenedione, and aza-anthracenedione derivatives, with comparable cytotoxicity but
lower cardiotoxicity. Mitoxantrone and pixantrone (see Figure 1) are two examples of
synthetic second generation anthracycline derivatives that exhibit significantly lower
cardiotoxicity but maintain potent anticancer activity.5-8 Similar to the parent anthracyclines,
the anthracenedione analogues can bind DNA by intercalation between the base pairs and
thereby induce their cytotoxic effect through the impairment of topoisomerase II.9-11 In
addition, in an attempt to develop an alternative pathway to anticancer activity,
anthracenediones have also been used to target G-quadruplex DNA structures.12,13 Recently,
it has been demonstrated that daunorubicin, mitoxantrone and pixantrone can form drug-DNA
covalent adducts at the N-2 amino groups of guanine nucleotides after activation by
formaldehyde.14-16 As the anthracenedione analogues are more cytotoxic to cells and solid
tumours that produce higher levels of formaldehyde, it has been proposed that covalent bond
formation is an important contributing mechanism to the anticancer properties of these
compounds. Additionally, it has been established that the combination of an anthracycline
drug and a formaldehyde-releasing pro-drug is synergistic in cancer cell lines, and leads to
apoptosis independently of topoisomerase II-mediated damage.17-19
Daunorubicin can only form one formaldehyde-mediated covalent bond with DNA (a
N-CH2-N link), whereas, mitoxantrone and pixantrone can potentially form two covalent
bonds, as they each contain two potentially reactive amine groups. Mitoxantrone-DNA
adducts have a half-life of 50 minutes and appear to be formed between the secondary amine
of one side chain and the N-2 of guanine at a CpG sequence.20 The more recently synthesised
anthracenedione pixantrone forms DNA adducts 10- to 100-fold more efficiently at CpG sites
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than mitoxantrone and while the pixantrone-DNA adducts are still labile, they are more stable
than those formed by mitoxantrone.21 Previously, Phillips, Cutts and co-workers have also
shown that pixantrone and mitoxantrone form 2-5 fold more covalent adducts at 5'-CpG
sequences when the cytosine is methylated at the C-5 position.22 The cytosine residue in CpG
sequences (found disproportionately in regulatory promoter regions) is often methylated, with
methylation typically occurring after DNA replication.23

Figure 1.

Structure of daunorubicin, mitoxantrone, pixantrone and WEHI-150. The
atom numbering of WEHI-150 is also given.

A bis-amino mitoxantrone analogue, named herein WEHI-150 (see Figure 1), was
synthesised in an attempt to develop anthracenedione analogues that are more reactive with
DNA than mitoxantrone and pixantrone, but are also more likely to form covalent cross-links
between the two DNA strands, through the formation of an adduct with a covalent bond to a
guanine residue on each strand of the duplex.24,25 By the replacement of the terminal
hydroxyl group on each mitoxantrone side chain with an amine group, it was hypothesised
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that WEHI-150 would be able to rapidly form covalent linkages with DNA and more
importantly, it would be able to form multiple covalent linkages with DNA. DNA sequence
specific in vitro transcription studies revealed probable interstrand cross-linking sites for
WEHI-150.25
In this study we have examined by mass spectrometry and HPLC the ability of WEHI150 to form covalent adducts with oligonucleotides that contain either a CpG or a 5methylated cytosine in the CpG (5MeCpG) site. As the results indicated that WEHI-150
readily forms multiple covalent adducts with DNA, and to a significantly greater extent when
the oligonucleotide contains a 5MeCpG site, we have also examined the reversible intercalative
binding of WEHI-150 at both CpG and 5MeCpG sites by NMR spectroscopy and molecular
modelling. The mode of reversible binding of WEHI-150 at the CpG sequence (i.e. from the
major or minor groove), will affect the rate of adduct formation with the guanine N-2 amino
group that is located in the minor groove. It has been established by x-ray studies that
daunorubicin intercalates at CpG sites from the DNA minor groove,26 whereas, mitoxantrone
and pixantrone bind from the major groove.27,28 However, in the NMR study of the binding
of pixantrone to the octanucleotide d(ACGATCGT)2 some non-intercalative minor groove
binding was also observed. It was proposed that this small population of minor groove bound
pixantrone could be responsible for the guanine N-2 adducts.28

Experimental
Materials
Oligonucleotides were obtained from GeneWorks, South Australia. D2O (99.9% D) was
obtained from Cambridge Isotope Laboratories, and CM-Sephadex from AmershamPharmacia-Biotech. Formaldehyde (37% solution) was purchased from Sigma-Aldrich (St
Louis, USA). Ammonium acetate (NH4OAc), acetonitrile (ACN, HPLC grade) and ammonia
were obtained from Ajax Finechem (Seven Hills, Australia), while methanol was obtained
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from Aldrich chemical company. De-ionised Milli-Q water was used for all the experiments.
Pixantrone (BBR 2778) was kindly supplied by CTI BioPharma, Seattle, while mitoxantrone
and daunorubicin were purchased from Sigma-Aldrich. WEHI-150 was synthesised as
previously described.29

Sample preparation for mass spectrometry
A d(ACGCGCGT)2 solution (1 mM) was obtained by annealing the appropriate amounts of
the self-complementary oligonucleotide in 100 mM ammonium acetate, pH 7.5, by heating to
90 °C for 15 min and then allowing the sample to cool slowly to room temperature. Drug
stock solutions were prepared by dissolving the appropriate amount in 100 mM ammonium
acetate to obtain a final concentration of 1 mM. All stock solutions were stored at -20 °C
until required for experiments. DNA-drug cross-linking samples were prepared by adding the
appropriate amount of double-stranded DNA (1 mM stock) and drug (1 mM stock) to obtain a
1:5 molar ratio with a final DNA concentration of 40 µM in 100 mM ammonium acetate.
Solutions were left to equilibrate for one hour, then formaldehyde was added to the DNAdrug mixture to obtain a formaldehyde concentration of 2 mM. Samples were incubated at
room temperature (21 °C) for six hours and then 10 µL of the mixture was taken and diluted
just prior to ESI-MS analysis with 70 µL of 100 mM ammonium acetate and immediately
analysed.

Mass spectrometry
All drug-DNA complexes were analysed under the same instrumental conditions using a
Waters Q-Tof Ultima™ ESI mass spectrometer equipped with a Z-spray ionisation source and
a quadrupole mass analyser with a m/z range of 32,000. Samples were injected into the mass
spectrometer at a flow rate of 20 µL/min using a Harvard Model 22 syringe pump (Natick,
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MA, USA). All spectra were acquired using a MCP potential of 1850V, Rf lens energy of
70V, capillary voltage of 2.50 kV and sampling and extraction cone voltages were 70V and 4
V, respectively. The source temperature was 80 °C and the desolvation gas flow rate was 300
L/h at a temperature of 120 °C. All spectra were acquired in negative ion mode over the
range m/z 500-4000 and typically 30 acquisitions were combined to obtain a representative
spectrum. Each spectrum was then background subtracted using a polynomial order of 2 with
20% below curve, then smoothed using the MassLynx software, where 10 channels were
smoothed twice. Prior to analysis the instrument was externally calibrated with a solution of
1 mg/mL caesium iodide (CsI) over the m/z acquisition range.

Sample preparation for HPLC
Oligonucleotides solutions (20 µΜ) were incubated with WEHI-150 (40 µΜ) and
formaldehyde (2 mM) in 100 mM ammonium acetate pH 6.8 at 37 °C for 10 hours, then the
un-reacted (including the reversibly bound) WEHI-150 was removed by phenol/chloroform
extraction and the DNA precipitated by the addition of absolute ethanol. The WEHI-150DNA adducts, a blue precipitate, were dissolved in 100 mM ammonium acetate pH 6.8 prior
to injection into the HPLC.

HPLC
HPLC analysis was performed on a Shimadzu prominence (UFLC) instrument, consisting of
an auto sampler (SIL-20AHT), pump (LC-20AD) and PDA detector (SPD-M20A). UV/Vis
detection, 260 nm for DNA and 660 nm for the WEHI-150, was used. The reaction between
WEHI-150 and the oligonucleotide was monitored by HPLC where mobile phase A was 0.1%
TEA in water pH 7 adjusted with acetic acid and mobile phase B was HPLC grade acetonitrile
with 10% water. A C18 column, 4.6 x 150 mm, 5 micron, reverse phase (Alltech Apollo) was
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used at room temperature at a flow rate of 1.0 mL/min. The chromatography gradient elution
was: 0 min, 0% B; 30 min, 30% B; 40 min, 50% B; 50 min, 50% B.

Sample preparation for NMR
Oligonucleotides were purified from minor impurities by passing them through a C18 SepPak cartridge and then converted to the sodium salt using a CM-Sephadex C-25 ion exchange
resin column, as previously described.30 The oligonucleotide was dissolved in 650 µL of
phosphate buffer (pH 7.0), containing 20 mM NaCl and 1 mM Na2H2EDTA, and the solution
was freeze-dried. Finally the oligonucleotide was dissolved in 650 µL of 99.9% D2O and the
solution heated to 90 °C and then cooled slowly to achieve the most stable duplex
conformation prior to use. The concentration of the oligonucleotide was estimated by the UV
absorbance (at A260), using an extinction coefficient of 6,600 M-1cm-1 per nucleotide. Stock
solutions of WEHI-150 were prepared in 99.9% D2O, and directly added to the NMR tube
containing the oligonucleotide and the 1H NMR spectrum recorded.

NMR Spectroscopy
NMR experiments were recorded at 400 MHz for the 1H nuclei using a Varian Unityplus-400
spectrometer at 25 °C unless otherwise stated and the data processed using the Agilent
software Vnmrj 2.2C. Chemical shift values were referenced to HDO at 4.78 ppm relative to
2,2-dimethylsilapentane-5-sulfonic acid. One- and two-dimensional spectra were recorded in
99.9% D2O for the non-exchangeable protons whereas for the exchangeable protons, spectra
were recorded in 90% H2O/10% D2O using the WET solvent suppression technique. Phasesensitive NOESY spectra were acquired using the method of States et al.,31 with 2048 data
points in t2 and 256 in t1 values with pulse repetition delay of 1.7 s for mixing time ranging of
100 and 300 ms. DQFCOSY spectra were recorded using the same t2, t1 and pulse repetition
delay as stated above.
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Molecular modelling
Molecular modelling was performed using HyperChem 7.5 software. Double helix B type
oligonucleotide was generated from the nucleic acid database and energy restraints were
added to preserve the hydrogen bonding between base pairs expected of duplex DNA during
the optimisation procedure, which were conducted in vacuo using the Amber 99 force field
and a Polak-Ribiere conjugant-gradient algorithm with 5 x 10-5 kcal/(Å mol) convergence
criteria.
The point charges of WEHI-150 were determined from semi-empirical calculations
using the AM1 program. The WEHI-150 complex point charges resulting from different
AM1 calculations appeared to vary only slightly with the conformation. Therefore, the point
charges resulting from an optimised confirmation were used to approximate the charges for
the subsequent molecular modelling AMBER optimisations with the DNA oligonucleotide.
The compound was manually inserted into the free DNA model to reflect the intermolecular
NOEs observed with DNA protons. Energy restraints were applied to preserve the observed
intermolecular NOEs and base pair hydrogen bonds during the subsequent interactive
optimization using AMBER and then the restraints were removed to confirm the resulting
structure was an energy minimised structure.

Results
Mass spectrometry analysis of covalent binding
Mass spectrometry was used to identify drug-oligonucleotide complexes, both reversibly
bound and covalent adducts, for WEHI-150 and the control anthracenedione drugs
daunorubicin, mitoxantrone and pixantrone. Preliminary experiments indicated that under the
conditions used the hexanucleotide sequence d(CGCGCG)2 was not stable in the gas phase
and mostly separated into its single strands, with only small amounts of the free and drugbound duplex being observed. Consequently, to increase duplex stability and the intensity of
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the observed drug-DNA adducts the octanucleotide d(ACGCGCGT)2 was used for the mass
spectrometry experiments. For the covalent adducts, it was possible to determine the number
of covalent CH2 links each drug formed with the oligonucleotide. Ionisation by electrospray
produces a range of charge states for oligonucleotides as a function of the sequence and
length, and for d(ACGCGCGT)2 the charge states of 4- and 3- were observed as the most
abundant species in the spectrum under the conditions used. While it was noted that some
drug-DNA adducts contained one and two bound drugs, and a very small proportion
contained three bound drugs (spectra not shown), the nature of the DNA used (a selfcomplementary sequence) created peak overlap for some of the charge states (single- versus
double-stranded). Although the resolution obtained in each spectrum allows determination of
the exact number of covalent CH2 links each adduct formed with the oligonucleotide, it was
not possible to unambiguously attribute the proportion of CH2 cross-links made to the
oligonucleotide for each drug when more than one drug was bound. In order to avoid any of
these issues, the 3- charge state was examined in detail, with a focus on the duplex with only
one drug, either reversibly or covalently bound. Table 1 shows that the obtained m/z values
for the drug-oligonucleotide complexes containing one bound drug were in agreement with
the calculated m/z values.
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Table 1.

Calculated and experimental m/z values for reversible and covalent drug-DNA
complexes for d(ACGCGCGT)2 with one drug bound for the 3- charge state.
Numbers in bracket indicate the obtained m/z values. (ND = Not Detected).

[DNA] 3Alone

Drug

0 CH2
(Reversible
binding)

1 CH2

2 CH2

3 CH2

4 CH2

1606.06
(1606.26)

Daunorubicin
Mwt 527.53

1781.90
(1781.85)

1785.91
(1785.90)

--

--

--

1606.06
(1606.02)

Mitoxantrone
Mwt 444.49

1754.22
(1754.22)

1758.22
(1758.12)

1762.22
(ND)

--

--

1606.06
(1606.10)

Pixantrone
Mwt 325.37

1714.52
(1714.52)

1718.52
(1718.54)

1722.52
(ND)

--

--

1606.06
(1606.35)

WEHI-150
Mwt 442.52

1753.57
(1753.58)

1757.57
(1757.54)

1761.57
(1761.52)

1765.57
(1765.50)

1769.57
(ND)

Figure 2 shows the 1700 to 1820 m/z region of the mass spectra of the drugoligonucleotide complexes after a 6-hour incubation with formaldehyde. Control experiments
were conducted to determine the effect of the addition of 2 mM formaldehyde to the
oligonucleotide in the absence of drug. No significant changes were observed in the mass
spectrum, indicating that formaldehyde did not react with the oligonucleotide (data not
shown). As observed in Figure 2, the bulk of the single bound daunorubicin existed as a
covalent adduct containing one covalent link to the oligonucleotide. This is the expected
result, as daunorubicin contains only one amine group; however, of note is the almost absence
of any reversibly bound daunorubicin. For mitoxantrone, only a relatively small proportion of
the bound drug is covalently linked to the oligonucleotide, with the reversibly bound species
dominating. While mitoxantrone is theoretically capable of forming adducts with two
covalent links to the oligonucleotide, only adducts with one covalent linkage were observed.
Similar results were observed for pixantrone, although the proportion of the covalent adduct
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was significantly greater. Interestingly, the profile for WEHI-150 was different to that of the
other drugs. Although not to the same degree as observed with daunorubicin, the proportion
of covalently bound oligonucleotide adducts was greater than that of the reversibly bound
WEHI-150. Furthermore, adducts with one, two and even three covalent links to the
oligonucleotide were observed.
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Figure 2.

Mass spectra showing the adducts formed after a 6-hour incubation at room
temperature of d(ACGCGCGT)2 with daunorubicin (A), mitoxantrone (B),
pixantrone (C) and WEHI-150 (D) in the presence of formaldehyde at 1:5 ratio
of DNA duplex to drug with [DNA= 5 µM]. The spectra show the 1770-1820
m/z region where the drug-DNA adducts charge state is 3- with one bound
drug. Numbered empty shapes () indicate the number of CH2 cross-links
formed between the double stranded DNA and the drug. Zero indicates
reversible binding by the drug. Note: peaks around m/z 1740 in (A) correspond
at 2 drugs for single stranded 2- charge state with m/z 1737 = 1 CH2 and m/z
1743 = 2 CH2. The peaks around m/z 1800 in (B) are of unknown origin.
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HPLC analysis of covalent binding
While the results from the mass spectrometry experiments demonstrated that WEHI-150
could form one, two or three covalent bonds with d(ACGCGCGT)2, it was not possible to
determine the extent of the covalent adducts that were formed relative to unreacted and
reversibly-bound oligonucleotide. Consequently, HPLC was used to examine the extent of
covalent bond formation of WEHI-150 with d(CGCGCG)2 and d(CG5MeCGCG)2. Figure 3
shows the HPLC elution profiles of the oligonucleotide mixtures obtained after WEHI-150
was incubated with either d(CGCGCG)2 or d(CG5MeCGCG)2 in the presence of formaldehyde
and then repeatedly extracted with a phenol/chloroform solution before being precipitated by
the addition of ethanol. With d(CGCGCG)2, three approximately equal small product peaks
(1', 2' and 3') were observed in the HPLC profile, along with a large peak for the free
oligonucleotide. Virtually all non-covalently bound WEHI-150 was removed by the
phenol/chloroform extraction after the incubation of the drug with the oligonucleotide. In
addition, any remaining small amount of reversibly bound drug dissociates from the
oligonucleotide on the HPLC column and is separately eluted after the three small peaks seen
in Figure 3, at approximately 27 minutes. Consequently, the observed small peaks can be
identified as covalent adducts due to their characteristic WEHI-150 UV/Vis absorption at 660
nm. By contrast, incubation of WEHI-150 with d(CG5MeCGCG)2 in the presence of
formaldehyde resulted in the formation of a significantly greater amount of covalent adducts.
Of further note, only one major covalent adduct was observed in the HPLC elution profile,
possibly suggesting preferential binding at the 5MeCpG site.
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A

1

1
1ꞌ

2ꞌ

3ꞌ

B

Figure 3.

HPLC elution profiles of the oligonucleotide mixture obtained after incubation
with WEHI-150 in the presence of formaldehyde. A: d(CGCGCG)2, where the
free DNA peak is denoted as 1 and the WEHI-150-DNA covalent adducts 1', 2'
and 3'. B: d(CG5MeCGCG)2, where the free oligonucleotide peak is denoted as
2 and the dominant covalent adduct 2*.
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NMR analysis of reversible binding at CpG and 5MeCpG sites
As the HPLC experiments indicated that WEHI-150 formed significantly more covalent
adducts with d(CG5MeCGCG)2 than with the corresponding non-methylated oligonucleotide in
the presence of formaldehyde, an NMR study of the reversible interaction of the drug at both
CpG and 5MeCpG sites was undertaken. In order to simplify the analysis of the binding of
WEHI-150 at a CpG site, the octanucleotide d(ACGGCCGT)2 was used for the NMR
experiments. The octanucleotide contains two symmetric CpG sites (indicated in bold), rather
than the three potential CpG binding sites in d(CGCGCG)2. However, for the analysis of
WEHI-150 binding at a 5MeCpG site, the hexanucleotide d(CG5MeCGCG)2 was used, as this
oligonucleotide also allowed a comparison of the relative preference for a 5MeCpG compared
to the non-methylated dinucleotide.

Assignment of free WEHI-150
The aromatic protons in the 1H NMR spectrum of WEHI-150 were assigned using standard
one-dimensional COSY and NOESY NMR experiments and by comparison with the
previously reported assignments for mitoxantrone and pixantrone.28,32 The H6,7 protons were
assigned by the observation of a strong NOE to the Ha protons and weak NOEs to the Hb, Hc
and Hd protons.

WEHI-150 binding to d(ACGGCCGT)2
The resonances in the 1H NMR spectra of the free and WEHI-150 bound oligonucleotide
were assigned by standard techniques.33-35 Consistent with many NMR studies of
oligonucleotides,33-36 the analysis of short mixing-time NOESY and DQFCOSY spectra
indicated that the octanucleotide adopted a B-type conformation in the aqueous buffer.
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Figure 4 shows the spectra of the imino protons for the free and WEHI-150-bound
d(ACGGCCGT)2 at 10 oC. Two new sets of peaks, corresponding to 1:1 and 2:1 drug to
oligonucleotide duplex binding, were observed upon addition of WEHI-150 to the
oligonucleotide. This indicates that WEHI-150 binds the oligonucleotide with slow exchange
kinetics (on the NMR time scale). The observation of only three imino resonances at a drug
to oligonucleotide ratio of 2 indicates that the two WEHI-150 molecules were bound to
d(ACGGCCGT)2 in a symmetrical fashion, suggesting selective binding at the two CpG sites.
Significant upfield shifts were observed for the imino resonances from the G3 and G7, again
consistent with intercalation at both the C2pG3 and C6pG7 sites. Two new sets of peaks from
the aromatic protons of d(ACGGCCGT)2 were also observed upon addition of WEHI-150 to
the oligonucleotide (see Figure 5). Table 2 summarises the chemical shifts of the resonances
from the WEHI-150-bound oligonucleotide and the change in chemical shift upon addition of
WEHI-150 to a drug to duplex ratio of 2. The resonances from the WEHI-150 protons shifted
upfield (0.24 to 0.35 ppm, see Table 3), consistent with WEHI-150 binding by intercalation,
while the resonances from the aliphatic side chain protons shifted upfield but to a lesser
extent.
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Figure 4.

1

H NMR spectrum of the imino resonances of d(A1C2G3G4C5C6G7T8)2 (A) and

with added WEHI-150, at a drug to duplex ratio R = 0.8 (B), R = 1.4 (C) and R
=1.9 (D) at 10 °C, in 90%/10% H2O/D2O in pH 7 phosphate buffer. In the
spectra, * represents 1:1 drug to oligonucleotide binding, while # indicates 2:1
binding.

Figure 5.

1

H NMR spectra of the titration of d(A1C2G3G4C5C6G7T8)2 with WEHI-150.

(A) free oligonucleotide, (B) with added WEHI-150 to DNA duplex ratio (R)
of 0.8 (C) with added WEHI-150 at R = 1.4 (aromatic region). In the spectra, *
represents 1:1 drug to oligonucleotide binding, while # indicates 2:1 binding.
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Table 2.

H NMR assignment of the resonances of d(A1C2G3G4C5C6G7T8)2 with added

WEHI-150 at R = 2, at 25 °C in pH 7 phosphate buffer. * Imino proton shifts
were recorded at 10 °C. Changes in chemical shift upon WEHI-150 binding
are given in brackets, with a negative sign indicating an upfield shift.
Base
A1
C2
G3
G4
C5
C6
G7
T8

H8/H6

AH2/CH5

H1'

H2'

H2''

8.25
(+0.05)
7.44
(+0.01)
8.09
(+0.22)
7.71
(-0.09)
7.39
(+0.01)
7.52
(+0.10)
8.27
(+0.27)
7.49
(+0.04)

7.95
(-0.09)
5.36
(-0.14)

6.21
(-0.01)
5.42
(+0.01)
5.86
(+0.19)
5.81
(-0.14)
5.88
(-0.09)
5.63
(0.00)
6.09
(-0.03)
6.28
(+0.02)

2.62
(0.00)
2.09
(-0.01)
2.73
(+0.03)
2.60
(-0.01)
2.08
(0.00)
1.93
(+0.01)
2.70
(-0.04)
2.26
(-0.01)

2.80
(+0.06)
2.36
(-0.01)
2.73
(-0.04)
2.60
(-0.14)
2.47
(-0.01)
2.27
(-0.07)
2.36
(-0.38)
2.65
(+0.38)

Table 3.

1

5.17
(-0.13)
5.57
(-0.03)

Methyl

Imino*

12.63
(-0.51)
13.04
(+0.02)

12.41
(-0.53)
1.37
(-0.32)

H NMR shifts of free WEHI-150 and WEHI-150 bound to d(ACGGCCGT)2

and d(CG5MeCGCG)2 at drug to DNA ratios (R) = 2 and 1, respectively, in pH
7 phosphate buffer. Changes in chemical shift are given in brackets, with a
negative sign indicating an upfield shift.
WEHI-150
protons

H2,3

H6,7

Ha

Hb

Hc

Hd

Free

7.24

7.46

3.91

3.49

3.47

3.42

d(ACGGCCGT)2
Bound
d(CG5MeCGCG)2
Bound

7.00
(-0.24)
6.65
(-0.59)

7.11
(-0.35)
6.76
(-0.70)

3.81
(-0.10)
3.35
(-0.56)

3.38
(-0.11)
2.97
(-0.52)

3.49
(+0.02)
3.30
(-0.17)

3.53
(+0.11)
3.27
(-0.15)
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NOESY spectra were recorded to obtain a detailed picture of the WEHI-150oligonucleotide binding. Strong intermolecular NOEs were observed from the WEHI-150
H2,3 to the H1' protons of G3 and G7 and from the H6,7 protons to the H5 protons of C2 and
C6 (see Figure 6). In addition, weak NOEs were also observed from the H6,7 protons of the
WEHI-150 to the H6 protons of C2 and C6. These NOEs indicate that WEHI-150
preferentially binds at the CpG sites of the oligonucleotide as expected. Furthermore, NOEs
between the ethylene side chain protons of WEHI-150 and the major groove protons of the C2
and C6 were also observed. Taken together, the observed pattern of intermolecular NOEs
indicates that WEHI-150 intercalates at CpG sites from the major groove.

Figure 6.

An expansion of a NOESY spectrum of d(A1C2G3G4C5C6G7T8)2 with added
WEHI-150, at a ratio of R = 0.8 to DNA at 20 °C. It shows the NOE
connectivities from the aromatic protons C2H5, C6H5 and G3, G7 sugar H1'
protons of the oligonucleotide to the WEHI-150 H6,7 and H2,3 respectively.
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WEHI-150 binding to d(CG5MeCGCG)2
The addition of WEHI-150 to d(CG5MeCGCG)2 induced an upfield shift for the G4 imino
resonance (see Figure 7), suggesting that WEHI-150 bound at the 5MeCpG site. Significant
upfield shifts (0.59 to 0.70 ppm, see Table 3) were observed from the WEHI-150 aromatic
protons upon addition to d(CG5MeCGCG)2, consistent with WEHI-150 binding by
intercalation. Interestingly, the resonances from the Ha and Hb aliphatic side chain protons
also shifted considerably upfield. While the aromatic resonances from the oligonucleotide
generally broadened upon addition of WEHI-150, multiple peaks for the H6 of the 5MeC3 were
observed (see Table 4 and Figure 8), suggesting there were at least two binding modes in slow
exchange.

Figure 7.

1

H NMR spectra of the imino resonances of the d(C1G25MeC3G4C5G6)2 A, with

added WEHI-150 at R = 1 B, at 10 °C in 90%/10% H2O/D2O in pH 7
phosphate buffer. G2 and G4 imino protons of the free and bond
oligonucleotide are indicated.
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Table 4

1

H NMR assignment of the resonances of d(C1G25MeC3G4C5G6)2 with added

WEHI-150 at R = 1 in pH 7 phosphate buffer at 30 °C. * Imino proton shifts
were recorded at 10 °C. Changes in chemical shift upon WEHI-150 binding
are given in brackets, with a negative sign indicating an upfield shift.
Bases
C1

G2

5Me

C3

H8/H6
7.63
(-0.04)
7.59
(-0.08)
7.97
(-0.04)
7.90
(-0.11)
7.15
(-0.03)
7.21
(+0.03)
7.07
(-0.11)

G4

7.87
(-0.07)

C5

7.31
(-0.05)

G6

7.89
(-0.07)

H5

H1'

H2'

H2"

5.82
(-0.12)

5.73
(-0.07)

2.00
(-0.03)

2.35
(-0.09)

5.97
(-0.08)

2.66
(-0.02)

2.82
(-0.04)

5.65
(-0.04)

1.98
(-0.05)

2.39
(0.00)

5.86
(-0.03)

2.69
(-0.02)

2.69
(-0.02)

5.80
(-0.06)

1.95
(+0.01)

2.32
(-0.05)

6.08
(-0.10)

2.61
(-0.03)

2.39
(-0.01)

5.71
(+0.02)

5.36
(-0.11)

Methyl

Imino*

13.17
(-0.01)
1.61
(-0.06)
1.54
(-0.13)
13.12
(-0.09)
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Figure 8. Aromatic region of the 1H NMR spectrum of free d(CG5MeCGCG)2 (A) and with
added WEHI-150 at 30 °C in 10 mM phosphate buffer pH 7.0, at a drug to duplex
ratio (R) of 0.25 (B), (C) R = 0.37, (D) R = 0.5, (E) R = 1.0, free WEHI-150 (F).
The H8 and H6 protons of the hexanucleotide and the H2,3 and H6,7 protons of
the free and bound WEHI-150 are indicated.

Figure 9 shows an expansion of a NOESY spectrum of d(CG5MeCGCG)2 with added
WEHI-150. An intermolecular NOE was observed between the WEHI-150 H2,3 protons to
the H2" proton of the 5MeC3. In addition, NOEs were also observed from the WEHI-150
aliphatic protons to the H1' proton of G4. These unambiguous NOEs indicate that WEHI-150
predominantly intercalates via the minor groove at the 5MeCpG site. However, additional
weak NOEs were also observed from WEHI-150 aliphatic protons to the H8 and H6 protons
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of the G4 and 5MeC3 protons, indicating that some proportion of WEHI-150 also intercalates
via the major groove.

Figure 9.

An expansion of a NOESY spectrum of d(CG5MeCGCG)2 with added
WEHI-150, at a drug to DNA duplex ratio of 1, at 35 °C in D2O and pH 7
phosphate buffer. The expansion shows the NOE connectivities from the
WEHI-150 H2,3 and Ha, Hc and Hd protons (3.1-3.45 ppm) to the
octanucleotide H2" of the 5MeC3 and H1' of the G4 protons respectively.

Molecular modelling
Mass spectrometry indicated that WEHI-150 could form multiple covalent bonds with a 5'GCGC duplex sequence, and NMR studies indicated that covalent bond formation occurred
when the drug predominantly intercalated from the minor groove. Due to the broad and
overlapping resonances from the two binding forms, the NMR data did not allow the
determination of a quantitative structure of WEHI-150 intercalated at the 5'-5MeCpG site of
d(CG5MeCGCG)2. However, simple HyperChem binding models were constructed to examine
the feasibility of WEHI-150 forming two to four covalent bonds with the four guanine
residues in a 5'-G5MeCGC duplex sequence. Molecular models were constructed (see Figure
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10) with the WEHI-150 intercalated (non-covalently bound) from the minor groove at the 5'5Me

CpG site of the hexanucleotide d(CG5MeCGCG)2. The WEHI-150-oligonucleotide

structure is consistent with the intermolecular NOEs observed in the NMR experiments.
Models were examined where the WEHI-150 was intercalated from the major groove at the
5'-5MeCpG site; however, the distances between the WEHI-150 and oligonucleotide protons
that gave NOE cross-peaks in NOESY spectra were significantly greater than the maximum
distance (5 Å) for which an NOE can be observed. For example, a strong intermolecular
NOE was observed between the WEHI-150 aliphatic Ha proton and the G4H1' from
d(CG5MeCGCG)2: the minimum distance between these protons for the drug intercalated from
the major groove was 9.25 Å; whereas the distance with WEHI-150 intercalated from the minor
groove was 3.3 Å. The model clearly demonstrates that, in principle, WEHI-150 can readily
form between one and four covalent bonds with the four guanine residues in the 5'-G5MeCGC
duplex sequence. Unless the DNA is significantly distorted, the model suggests that when
WEHI-150 forms three covalent bonds, it must form an interstrand cross-link where each
strand of the duplex is covalently bound to the drug.
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Figure 10.

Energy minimized HyperChem model of WEHI-150 intercalated (noncovalently bound) at the 5MeCpG site via the minor groove. The guanine
residues are shown in yellow, the cytosine residues in grey, guanine NH2
groups are red, and the DNA backbone in cyan. The WEHI-150 is shown in
green and the primary and secondary amines of WEHI-150 are in blue.

Discussion
Anthracenedione compounds can bind DNA by intercalation and thereby exert anticancer
activity through the impairment of topoisomerase II.9,10 However, it has also been proposed
that anthracenedione drugs containing side chain amine groups can induce apoptosis in cancer
cells through formation of a covalent adduct with the N-2 amino group of a guanine residue at
CpG sites after activation by formaldehyde.14-16 The results of this study confirm that
daunorubicin, mitoxantrone and pixantrone can form covalent adducts with duplex DNA.
WEHI-150 was synthesised in an attempt to develop anthracenedione analogues that can form
covalent cross-links between the two DNA strands, through the formation of covalent bonds
to a guanine residue on each strand of the duplex. The results from this study indicate that
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WEHI-150 can form at least three covalent bonds with duplex DNA at GpCpGpC sequences
after activation by formaldehyde.
The HPLC results presented in this study demonstrated that WEHI-150 formed
considerably more covalent adducts with the hexanucleotide d(CG5MeCGCG)2, than with the
non-methylated hexanucleotide d(CGCGCG)2. Previous studies have demonstrated a 2-5
fold increase in covalent adducts with mitoxantrone and pixantrone when the DNA
contained 5MeCpG sequences.22 As the initial reversible binding of WEHI-150 at a CpG or
5Me

CpG site must to some degree influence the formation of the subsequent covalent bond

formation, an NMR study of WEHI-150 binding with d(CGCGCG)2 and d(CG5MeCGCG)2
was carried out. The results confirmed that WEHI-150 preferentially intercalated at CpG
sites, and demonstrated that the drug intercalated from the DNA major groove. This is
consistent with the results of previous NMR studies with the closely related analogues
mitoxantrone and pixantrone.27,28 Furthermore, the results demonstrated WEHI-150
preferentially intercalates at 5MeCpG sites, compared to CpG sites, and of greater
consequence, the drug predominantly intercalated from the minor groove at 5MeCpG
sequences.
Although pixantrone forms more covalent adducts at 5MeCpG sites than at CpG sites,
previous NMR studies have established that pixantrone predominantly intercalates from the
major groove at both 5MeCpG sites and CpG sites.28 However, some minor groove binding
was observed.28 Consequently, it is possible that the additional DNA adducts formed by
pixantrone at 5MeCpG sites could be due to the increased nucleophilicity of the guanine N-2
due to the electronic effect of the methylation of the complementary cytosine. For WEHI150, the electronic effects of C-5 methylation may contribute to the increased adducts formed
at 5MeCpG sites; however, the switching from intercalation from the major groove to the minor
groove is likely to be more important. It is not clear why WEHI-150, unlike pixantrone,
intercalates from the minor groove at 5MeCpG sites. Examination of molecular models
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suggests that there are no steric barriers to major groove intercalation at 5MeCpG sites for
either pixantrone or WEHI-150. Base stacking is the main driving force for the formation of
duplex DNA,37 and the stacking between an intercalated drug and the base pairs at the binding
site also provides favourable thermodynamic driving forces for the formation of the drugDNA complex.38 However, DNA groove-binding interactions are predominantly entropy
driven, and it has been established that intercalation is enthalpically driven.38 Consequently,
it is likely that the stacking interactions of WEHI-150 are maximised for minor groove
intercalation at 5MeCpG sites. In particular, the electrostatic dipole-dipole interactions
between WEHI-150 and the DNA base pairs are a significant stabilising force for the
intercalative binding, and play a role in determining the geometry of the binding. The
anthracenedione moiety of WEHI-150 produces a different pattern of dipole moments,
compared to the aza-anthracenedione pixantrone, which consequently results in a different
binding geometry – minor groove intercalation for WEHI-150, and major groove intercalation
for pixantrone.
Taken together, the results of this study demonstrate that WEHI-150 is likely to form
interstrand DNA cross-links. Although it is yet to be established, it is possible that the
interstrand cross-links formed by WEHI-150 would disrupt DNA-mediated processes to a
greater degree than anthracenedione drugs that are capable of forming only one covalent bond
with DNA. Furthermore, the observed reversible binding preference for 5MeCpG sites,
compared to CpG sites, could also potentiate the anticancer properties of WEHI-150. Gene
expression is largely affected by promoters, which often contain CpG “islands”.39 Although
cancer cells generally contain hypomethylated genomes, CpG islands are hypermethylated.39
Consequently, preferential binding in the DNA minor groove at the methylated CpG islands
in promoter regions could allow for the optimal activity of WEHI-150 through the formation
of covalent bonds with guanine residues after activation by formaldehyde.
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In conclusion, the results of this study indicate that WEHI-150 can form interstrand
cross-links with DNA after activation by formaldehyde. In addition, WEHI-150
predominantly intercalates from the DNA major groove at CpG sites, but from the minor
groove at 5MeCpG sequences. As intercalation at 5MeCpG sites is preferred compared to nonmethylated sites, WEHI-150 forms considerably more covalent adducts at sequences
containing 5MeCpG sites with adjacent guanine residues.
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